Sort by:
O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRĪ±)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gynecol Oncol. 2020;:ePub - PMID: 32081463 - DOI: 10.1016/j.ygyno.2020.01.037
1 CSV